VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28
November 21 2018 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announces it will
provide a corporate update, in a Fireside Chat format, at the Piper
Jaffray 30th Annual Healthcare Conference, to be held at the Lotte
New York Palace on November 27–29, 2017, in New York City.
Presentation Details: |
Date:Time:Location:Webcast: |
|
Wednesday, November
283:30-3:55 PM Eastern TimeSoHo Track - Hubbard 1, 5th
floorhttps://event.webcasts.com/starthere.jsp?ei=1220342&tp_key=0f7f922eb8 |
|
|
|
About VBLVascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. The
Company’s lead oncology product candidate, ofranergene obadenovec
(VB-111), is a first-in-class, targeted anti-cancer gene-therapy
agent that is positioned to treat a wide range of solid tumors. It
is conveniently administered as an IV infusion once every two
months. It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
trial for platinum-resistant ovarian cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”,
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
include, but are not limited to, statements regarding our programs,
including VB-111, including their clinical development, therapeutic
potential and clinical results. These forward-looking statements
are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, and that we may not realize the expected
benefits of our intellectual property protection. A further list
and description of these risks, uncertainties and other risks can
be found in the Company’s regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2017, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024